These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 30719039)

  • 1. The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States.
    Moore A; Stav I; Den RB; Gordon N; Sarfaty M; Neiman V; Rosenbaum E; Goldstein DA
    J Oncol; 2019; 2019():8170428. PubMed ID: 30719039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Financial Impact of Fractionation Scheme and Treatment Planning Method for Rectal Cancer in the United States.
    Moore A; Den RB; Gordon N; Sarfaty M; Kundel Y; Brenner B; Goldstein DA
    Clin Colorectal Cancer; 2019 Sep; 18(3):209-217. PubMed ID: 31255477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fractionation scheme and treatment planning method for early glottic cancer in the United States: Economic impact of different medical decisions.
    Moore A; Den RB; Popovtzer A; Goldvaser H; Gordon N; Goldstein DA
    Head Neck; 2020 Aug; 42(8):1713-1720. PubMed ID: 31976607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is moderate hypofractionation accepted as a new standard of care in north america for prostate cancer patients treated with external beam radiotherapy? Survey of genitourinary expert radiation oncologists.
    McClelland S; Sandler KA; Degnin C; Chen Y; Hung AY; Mitin TE
    Int Braz J Urol; 2019; 45(2):273-287. PubMed ID: 30676300
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypofractionation for clinically localized prostate cancer.
    Hickey BE; James ML; Daly T; Soh FY; Jeffery M
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
    Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
    Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
    Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
    Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
    Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
    Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
    Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
    Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can the Adoption of Hypofractionation Guidelines Expand Global Radiotherapy Access? An Analysis for Breast and Prostate Radiotherapy.
    Irabor OC; Swanson W; Shaukat F; Wirtz J; Mallum AA; Ngoma T; Elzawawy A; Nguyen P; Incrocci L; Ngwa W
    JCO Glob Oncol; 2020 Apr; 6():667-678. PubMed ID: 32343628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly Men.
    Trogdon JG; Falchook AD; Basak R; Carpenter WR; Chen RC
    JAMA Oncol; 2019 Jan; 5(1):60-66. PubMed ID: 30242397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient costs associated with external beam radiotherapy treatment for localized prostate cancer: the benefits of hypofractionated over conventionally fractionated radiotherapy.
    Sethukavalan P; Cheung P; Tang CI; Quon H; Morton G; Nam R; Loblaw A
    Can J Urol; 2012 Apr; 19(2):6165-9. PubMed ID: 22512958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis.
    Moschini M; Zaffuto E; Karakiewicz PI; Andrea DD; Foerster B; Abufaraj M; Soria F; Mattei A; Montorsi F; Briganti A; Shariat SF
    Eur Urol; 2019 Feb; 75(2):319-328. PubMed ID: 30293908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends and variations in utilization and costs of radiotherapy for prostate cancer: A SEER medicare analysis from 2007 through 2016.
    Mukherjee K; Small W; Duszak R
    Brachytherapy; 2022; 21(1):12-21. PubMed ID: 34380592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
    Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
    Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current use of stereotactic body radiation therapy for low and intermediate risk prostate cancer: A National Cancer Database Analysis.
    Malouff TD; Stross WC; Seneviratne DS; Waddle MR; May BC; Buskirk SJ; Tzou KS
    Prostate Cancer Prostatic Dis; 2020 Jun; 23(2):349-355. PubMed ID: 31780782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adoption of hypofractionated radiation therapy for breast cancer after publication of randomized trials.
    Jagsi R; Falchook AD; Hendrix LH; Curry H; Chen RC
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1001-9. PubMed ID: 25539365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypofractionated radiotherapy recommendations for localized prostate cancer in Brasil.
    Palhares DMF; Pimentel LCF; Castilho MS; Costa ABD; Reisner ML; Kuhnen FQ; Pássaro A; Leite ETT; Faustino FLC; Obst FM; Costa FNBBF; Pioner GT; Carvalho ÍT; Silva JLFD; Morikawa LKK; Zanuncio PHDR; Hanriot RM; Rosa AA
    Rev Assoc Med Bras (1992); 2021 Jan; 67(1):7-18. PubMed ID: 34161478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.